AU2011305568B2 - Imidazotriazinone compounds - Google Patents

Imidazotriazinone compounds Download PDF

Info

Publication number
AU2011305568B2
AU2011305568B2 AU2011305568A AU2011305568A AU2011305568B2 AU 2011305568 B2 AU2011305568 B2 AU 2011305568B2 AU 2011305568 A AU2011305568 A AU 2011305568A AU 2011305568 A AU2011305568 A AU 2011305568A AU 2011305568 B2 AU2011305568 B2 AU 2011305568B2
Authority
AU
Australia
Prior art keywords
alkyl
imidazo
trans
triazin
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011305568A
Other languages
English (en)
Other versions
AU2011305568A1 (en
Inventor
Andrew Mcriner
Amy Ripka
Gideon Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Publication of AU2011305568A1 publication Critical patent/AU2011305568A1/en
Assigned to FORUM PHARMACEUTICALS INC. reassignment FORUM PHARMACEUTICALS INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: ENVIVO PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2011305568B2 publication Critical patent/AU2011305568B2/en
Priority to AU2016200970A priority Critical patent/AU2016200970A1/en
Assigned to IRONWOOD PHARMACEUTICALS, INC. reassignment IRONWOOD PHARMACEUTICALS, INC. Request for Assignment Assignors: FORUM PHARMACEUTICALS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2011305568A 2010-09-20 2011-09-20 Imidazotriazinone compounds Ceased AU2011305568B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016200970A AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38469410P 2010-09-20 2010-09-20
US61/384,694 2010-09-20
PCT/US2011/052399 WO2012040230A1 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200970A Division AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Publications (2)

Publication Number Publication Date
AU2011305568A1 AU2011305568A1 (en) 2013-04-04
AU2011305568B2 true AU2011305568B2 (en) 2015-12-10

Family

ID=44720178

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011305568A Ceased AU2011305568B2 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds
AU2016200970A Abandoned AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016200970A Abandoned AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Country Status (16)

Country Link
US (3) US20120157458A1 (enExample)
EP (2) EP3181566A1 (enExample)
JP (2) JP5855109B2 (enExample)
CN (1) CN103313988B (enExample)
AR (1) AR083058A1 (enExample)
AU (2) AU2011305568B2 (enExample)
BR (1) BR112013008140A8 (enExample)
CA (1) CA2811714C (enExample)
DK (1) DK2619208T3 (enExample)
ES (1) ES2610360T3 (enExample)
MX (1) MX2013003093A (enExample)
PL (1) PL2619208T3 (enExample)
RU (1) RU2603140C2 (enExample)
TW (1) TWI541244B (enExample)
UY (1) UY33616A (enExample)
WO (1) WO2012040230A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181566A1 (en) * 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
MX381326B (es) * 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2807163B1 (en) * 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JP2018508555A (ja) * 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) * 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
IL295973A (en) 2016-07-06 2022-10-01 H Lundbeck As pde9 inhibitors for the treatment of peripheral diseases
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
HUE065158T2 (hu) * 2017-05-26 2024-05-28 Cardurion Pharmaceuticals Inc PDE9 gátlószereinek elõállítására és alkalmazására szolgáló eljárások
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
WO2020102374A1 (en) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Targeting of makap-pde4d3 complexes in neurodegenerative disease
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CA3155013A1 (en) * 2019-10-21 2021-04-29 Ki Ho Lee Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2006127368A2 (en) 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20090163521A1 (en) 2005-06-28 2009-06-25 Orchid Research Laboratories Limited Novel Pyrazolopyrimidinone Derivatives
PT2152712E (pt) * 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN

Also Published As

Publication number Publication date
US20170152265A1 (en) 2017-06-01
CN103313988A (zh) 2013-09-18
US20140330014A1 (en) 2014-11-06
TW201217381A (en) 2012-05-01
AR083058A1 (es) 2013-01-30
WO2012040230A1 (en) 2012-03-29
BR112013008140A2 (pt) 2017-12-05
CA2811714C (en) 2017-11-21
TWI541244B (zh) 2016-07-11
RU2603140C2 (ru) 2016-11-20
UY33616A (es) 2012-04-30
JP2016104747A (ja) 2016-06-09
HK1187908A1 (en) 2014-04-17
ES2610360T3 (es) 2017-04-27
MX2013003093A (es) 2013-10-28
EP3181566A1 (en) 2017-06-21
EP2619208B1 (en) 2016-11-09
BR112013008140A8 (pt) 2018-04-03
CN103313988B (zh) 2016-06-08
DK2619208T3 (en) 2017-01-30
JP2013540755A (ja) 2013-11-07
EP2619208A1 (en) 2013-07-31
PL2619208T3 (pl) 2017-03-31
US20120157458A1 (en) 2012-06-21
JP5855109B2 (ja) 2016-02-09
CA2811714A1 (en) 2012-03-29
RU2013118362A (ru) 2014-10-27
AU2011305568A1 (en) 2013-04-04
US9540380B2 (en) 2017-01-10
AU2016200970A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US9540380B2 (en) Imidazotriazinone compounds
AU2021264916B2 (en) Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
US9969742B2 (en) Imidazotriazinone compounds
AU2013213603B2 (en) PDE9 inhibitors with imidazo triazinone backbone
CN116209446B (zh) 作为毒蕈碱性乙酰胆碱受体m4的正向别构调节剂的7-(哌啶-1-基)-4h-嘧啶并[1,2-b]哒嗪-4-酮衍生物
EP3681885B1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
US20150065465A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
JP2019532985A (ja) ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
JP2025538190A (ja) Ｅｇｆｒキナーゼの分解のための化合物
AU2017353313A1 (en) (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
HK1234039A1 (en) Imidazotriazinone compounds
HK1187908B (en) Imidazotriazinone compounds
EP4640274A1 (en) Lpar1 inhibitors
WO2026060424A1 (en) Akt degrader compounds and uses thereof
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
OA18469A (en) Tricyclic compounds and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IRONWOOD PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: FORUM PHARMACEUTICALS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired